Stay updated with breaking news from Aaron Lisberg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The application is based on results of the phase 3 TROPION-Lung01 trial of datopotamab deruxtecan in nonsquamous non–small cell lung cancer (NSCLC), first presented at the 2023 European Society for Medical Oncology Congress.
Aaron Lisberg, MD, provides a look at an upcoming Rapid Readout program looking at the results of the TROPION-Lung01 study investigating Dato-DXd in previously treated patients with advanced/metastatic NSCLC.
Patients with previously treated, advanced NSCLC had longer progression-free survival with Dato-DXd than with docetaxel in a phase 3 study.
Patients with previously treated, advanced NSCLC had longer progression-free survival with Dato-DXd than with docetaxel in a phase 3 study.
Still some unanswered questions about benefit over other drug regimens, expert says